Journals / Ahi Evran Tıp Dergisi / 2023 / Cilt: 7 Sayı: 1

Cyclophosphamide Exerts an Anti-Metastatic Effect by Reducing the Expression of MMP-2 and -9 in Saos-2 Osteosarcoma Cells

Siklofosfamid, Saos-2 Osteosarkom Hücrelerinde MMP-2 ve -9'un Ekspresyonunu Azaltarak Anti-Metastatik Etki Gösterir

Pages
69–74
Publication Date
2023-04-16
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results shed light on molecular studies for the treatment of osteosarcoma cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Although osteosarcoma is the most common primary malignant bone tumor among adolescents and young adults, the molecular mechanisms underlying the development of cancer are not fully elucidated.
📊
Key Findings & Data:The aim of this study is to reveal the effect of CYC on Saos-2 cells at the molecular level by determining the expression levels of some matrix metalloprotease proteins (MMP-2 and MMP-9) of cancer progression-related genes.
💡
Conclusion & Impact:These results shed light on molecular studies for the treatment of osteosarcoma cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:kanser · siklofosfamid · MMP

Abstract

Purpose: Although osteosarcoma is the most common primary malignant bone tumor among adolescents and young adults, the molecular mechanisms underlying the development of cancer are not fully elucidated. Cyclophosphamide (CYC) is an alkylating antineoplastic agent widely used in the treatment regimens of various cancers and chronic inflammatory diseases. The aim of this study is to reveal the effect of CYC on Saos-2 cells at the molecular level by determining the expression levels of some matrix metalloprotease proteins (MMP-2 and MMP-9) of cancer progression-related genes. Materials and Methods: Cytotoxicity analyzes were performed by applying CYC to the developed human osteosarcoma (Saos-2) cell cultures. The determined dose of CYC was applied to the 2D cell lines for 12, 24 and 48 hours. As a result of agent application, the expression levels of MMPs, which are metastatic markers in these cultures, were determined by the immunocytochemical method. Results: While MMP-2 and MMP-9 protein expression levels increased in control (PBS) groups in correlation with the extent of duration in the cell cultures created, decreased with CYC administration. Conclusion: It was determined that the expression levels of genes that play a role in metastasis, such as MMP-2 and MMP-9, were decreased by CYC application to Saos-2 cells. These results shed light on molecular studies for the treatment of osteosarcoma cancer.

Özet

Amaç: Osteosarkoma, ergenler ve genç yetişkinler arasında en sık rastlanan primer malign kemik tümörü olmakla birlikte, kanser gelişiminin altında yatan moleküler mekanizmalar tam anlamıyla aydınlatılamamıştır. Siklofosfamid (CYC), çeşitli kanserlerin ve kronik inflamatuvar hastalıkların tedavi rejimlerinde oldukça yaygın kullanılan alkilleyici antineoplastik bir ajandır. Bu çalışmanın amacı, CYC’nin Saos-2 hücreleri üzerine olan etkisini kanser progresyonu ilişkili genlere ait bazı matriks metalloproteaz (MMP-2 ve MMP-9) proteinlerinin ekspresyon seviyelerini belirleyerek moleküler düzeyde ortaya koymaktır. Araçlar ve Yöntem: Geliştirilen insan osteosarkoma (Saos-2) hücre kültürlerinde CYC uygulanarak sitotoksisite analizleri yapıldı. Belirlenen dozda CYC, iki boyutlu hücre hatlarına 12, 24 ve 48 saatlik sürelerde uygulandı. Ajan uygulaması sonucunda bu kültürlerdeki metastatik belirteçler olan MMP’lerin ekspresyon seviyeleri immünositokimyasal yöntem ile belirlendi. Bulgular: MMP2 ve MMP-9 protein ekspresyon seviyeleri oluşturulan hücre kültürlerinde artan süre ile korele olarak kontrol (PBS) gruplarında artarken; CYC uygulaması ile birlikte azalmıştır. Sonuç: Saos-2 hücrelerine CYC uygulaması ile MMP-2 ve MMP-9 gibi metastazda rol oynayan genlerin ekspresyon düzeylerini azaltıldığı belirlendi. Bu sonuçlar osteosarkoma kanseri tedavisi için moleküler çalışmalara ışık tutacak niteliktedir.

🔖

Cite This Article

SARIBAŞ, G. S. (2023). Cyclophosphamide Exerts an Anti-Metastatic Effect by Reducing the Expression of MMP-2 and -9 in Saos-2 Osteosarcoma Cells. Ahi Evran Tıp Dergisi, Cilt: 7 Sayı: 1, 69–74. https://ajindex.com/articles/898814

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68(6):394-424
  2. Koutsogiannouli E, Papavassiliou AG, Papanikolaou NA. Complexity in cancer biology: is systems biology the answer? Cancer Med. 2013;2(2):164-177
  3. Yokota J. Tumor progression and metastasis. Carcinogenesis. 2000;21(3):497-503
  4. Ram Kumar RM, Boro A, Fuchs B. Involvement and clinical aspects of microRNA in osteosarcoma. Int. J. Mol. Sci. 2016;17(6):877
  5. Pautke C, Schieker M, Tischer T, et al. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res. 2004;24(6):3743-3748
  6. Coggins PR, Ravdin RG, Eisman SH. Clinical evaluation of a new alkylating agent: Cytoxan (cyclophosphamide). Cancer. 1960;13(6):1254-1260
  7. Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamide‐induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39(4):1403-1409
  8. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ. Osteosarcoma. JAAOS- J Am Acad Orthop Surg. 2009;17(8):515-527
  9. Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma overview. Rheumatol Ther. 2017;4(1): 25-43
  10. Lopez SG, Luderer U. Effects of cyclophosphamide and buthionine sulfoximine on ovarian glutathione and apoptosis. Free Radic. Biol. Med. 2004;36(11):1366-1377
  11. Kawabata TT, Chapman MY, Dong-Hyun K, Stevens WD, Holsapple MP. Mechanisms of in vitro immunosuppression by hepatocyte-generated cyclophosphamide metabolites and 4-hydroperoxy cyclophosphamide. Biochem. Pharmacol. 1990;40(5): 927-935
  12. Singh N, Nigam M, Ranjan V, et al. Resveratrol as an adjunct therapy in cyclophosphamide‐treated MCF‐7 cells and breast tumor explants. Cancer Sci. 2011;102(5):1059-1067
  13. Sliwowska I, Kopczyński Z. Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer. Wiad. Lek. 2007;60(5-6):241-247
  14. Wu ZS, Wu Q, Yang JH, et al. Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer. Int. J. Cancer Res. 2008;122(9):2050-2056
  15. Provatopoulou X, Gounaris A, Kalogera E, et al. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast ca